Mirna Therapeutics announced the completion of a $41.8 million Series D financing.
The company's second institutional financing was led by Baxter Ventures, joined by other new investors, Eastern Capital, Santé Ventures, Morningside Ventures, Rock Springs Capital, and Celgene Corporation.
|Searching for more deal information? Current Partnering offers the following options:|
Existing investors Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners, Correlation Ventures, and others, also participated in the financing.
The funding will enable Mirna to advance its lead microRNA (miRNA) therapeutic product candidate, MRX34, into Phase 1b and Phase 2 trials in 2016.
Indications for further development will be selected at the completion of Mirna’s ongoing Phase 1 trial in patients with hepatocellular carcinoma, other solid tumors and hematological malignancies.
The Company also plans to advance a second miRNA therapeutic candidate into clinical trials with the proceeds of this financing, as well as embark on a combination therapy development program.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies